Delivery Order SPE2DB20D1100-SPE2DB25FE0NG
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Gamunex-C 5 gram/50 milliliter vials with a ceiling value of $1,214.68. This is a firm fixed-price delivery order without set-aside designation, with an ultimate completion date of September 15, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $40,532.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials, with an ultimate completion date of August 22, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $14,651.28 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gamunex-C 10 gram/100 mL vials (100 mL quantity). This is a firm fixed-price, non-set-aside contract with a completion date of October 8, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $28,323.36 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 20 gram/200 mL vials on July 22, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a competitive award with no set-aside designation. The contractor will perform from its corporate headquarters location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gamunex-C 5 gram/50 milliliter vials valued at $3,644.04 with a completion date of October 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,926.40 to AmerisourceBergen Drug Corp for the supply of Gamunex-C, a 40 gram/400 mL immunoglobulin product, with an ultimate completion date of June 17, 2025. The award, issued May 27, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with a firm fixed price. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $18,314.10 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 10 gram/100 mL vials on August 27, 2025, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Gamunex-C 1 gram/10 milliliter vials with a ceiling value of $1,223.80 and a completion date of September 3, 2025. This non-set-aside, firm fixed-price delivery order represents a competitively awarded contract under the company's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), which is valued at $999.999 billion through December...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0NGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $28,323.36 to AmerisourceBergen Drug Corp for the supply of Gamunex-C 20 gram/200 mL vials on September 18, 2025, with completion targeted for October 9, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $1 billion through December 2026. The company, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran healthcare systems. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply vehicle with the DLA, which enables the company to deliver a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally. The firm fixed-price structure and competitive award reflect the company's established capability to meet federal procurement requirements. The product—Gamunex-C, an immunoglobulin medication—supports the Defense Health Agency's medical supply requirements and demonstrates AmerisourceBergen's role as a critical vendor for specialized pharmaceutical needs within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.3k | 9/18/25 |